...
首页> 外文期刊>Journal of chemical information and modeling >Pharmacophore Identification,in Silico Screening,and Virtual Library Design for Inhibitors of the Human Factor Xa
【24h】

Pharmacophore Identification,in Silico Screening,and Virtual Library Design for Inhibitors of the Human Factor Xa

机译:药效基团鉴定,计算机筛选以及人因子Xa抑制剂的虚拟文库设计

获取原文
获取原文并翻译 | 示例
           

摘要

Factor Xa inhibitors are innovative anticoagulant agents that provide a better safety/efficacy profile compared to other anticoagulative drugs.A chemical feature-based modeling approach was applied to identify crucial pharmacophore patterns from 3D crystal structures of inhibitors bound to human factor Xa(Pdb entries 1fjs,1kns,leqz)using the software LIGANDSCOUT and CATALYST.The complex structures were selected regarding the criteria of high inhibitory potency(i.e.all ligands show K_i values against factor Xa in the subnanomolar range)and good resolution(i.e.at least 2.2 A)in order to generate selective and high quality pharmacophore models.The resulting chemical-feature based hypotheses were used for virtual screening of commercial molecular databases such as the WDI database.Furthermore,a ligand-based molecular modeling approach was performed to obtain common-feature hypotheses that represent the relevant chemical interactions between 10 bioactive factor Xa inhibitors and the protein,respectively.In a next step a virtual combinatorial library was designed in order to generate new compounds with similar chemical and spatial properties as known inhibitors.The software tool ILIB DIVERSE was used for this procedure in order to provide new scaffolds of this group of anticoagulants.Finally we present the combination of these two techniques,hence virtual screening was performed with selective pharmacophore models in a focused virtual combinatorial database.De novo derived molecular scaffolds that were able to adequately satisfy the pharmacophore criteria are revealed and are promising templates for candidates for further development.
机译:因子Xa抑制剂是创新的抗凝剂,与其他抗凝药物相比具有更好的安全性/有效性。基于化学特征的建模方法被用于从与人因子Xa结合的抑制剂的3D晶体结构中识别关键的药效团模式(Pdb条目1fjs使用LIGANDSCOUT和CATALYST软件,选择1kns,leqz。根据高抑制力(即所有配体对Xa因子在亚纳摩尔范围内显示K_i值)和良好的拆分度(即至少2.2 A)的条件选择复杂的结构为了产生选择性和高质量的药效基团模型,将所得的基于化学特征的假设用于虚拟筛选商业分子数据库,例如WDI数据库。此外,进行了基于配体的分子建模方法,以得到具有共同特征的假设,代表10种生物活性因子Xa抑制剂与蛋白质之间的相关化学相互作用下一步,设计了一个虚拟组合库,以生成具有与已知抑制剂相似的化学和空间特性的新化合物。此过程使用软件工具ILIB DIVERSE来提供该组抗凝剂的新支架最后,我们介绍了这两种技术的结合,然后在集中的虚拟组合数据库中使用选择性药效团模型进行了虚拟筛选。揭示了能够充分满足药效团标准的从头衍生的分子支架,它们有望成为候选药物的模板进一步的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号